A.N. Chremos - Concepedia

Author

A.N. Chremos

United States Military Academy

Also Known As

A N Chremos, A. N. CHREMOS, A. N. Chremos, A.N. Chremos, AN Chremos, Athanassios N Chremos

Publications

Citations

H-Index

Concepts

All Affiliations

United States Military Academy Merck & Co., Inc., Rahway, NJ, USA (United States)Baylor College of Medicine University of Alabama at Birmingham Oklahoma Medical Research Foundation

About

A.N. Chremos is an author at United States Military Academy specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	564
2	Public Health	2	2	72
3	Epidemiology	2	2	72
4	Health Sciences	1	1	31
5	Biochemistry	1	1	47

A.N. Chremos

Publications

958

Citations

H-Index

Page 1

	Year	Citations
Famotidine, a New, Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison Syndrome John M. Howard, A.N. Chremos, Martin J. Collen, Gastroenterology MedicinePharmacological AgentClinical PharmacologyZollinger-ellison SyndromePharmacotherapy	1985	186
Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin Carlos A. Dujovne, A.N. Chremos, James L. Pool, The American Journal of Medicine ThrombosisVascular DiseaseCardiovascular DiseaseExpanded Clinical EvaluationCardiovascular Pharmacology	1991	110
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Charles L. Shear, Frank A. Franklin, Sandra S. Stinnett, Circulation	1992	82
Effects of sulindac and indomethacin on renal prostaglandin synthesis John R. Sedor, Susan L. Williams, A.N. Chremos, Clinical Pharmacology & Therapeutics	1984	71
Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man J H Lin, A.N. Chremos, K. C. Yeh, European Journal of Clinical Pharmacology UrologyRenal FunctionChronic Renal FailureMedicineKidney Failure	1988	51
Single‐dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies K. C. Yeh, A.N. Chremos, J H Lin, Biopharmaceutics & Drug Disposition	1987	48
Famotidine, a new H2-receptor antagonist J L Smith, Mohamed Gamal, A.N. Chremos, Digestive Diseases and Sciences BiochemistryMedicineMechanism Of ActionPharmacological AgentPharmacotherapy	1985	47
Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia Reagan H. Bradford, Charles L. Shear, A.N. Chremos, The American Journal of Medicine Metabolic SyndromeThrombosisLipid DisorderHealth PolicyCardiovascular Disease	1991	41
Comparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion Jerome R. Ryan, Ramón Vargas, F. Gilbert McMahon, The American Journal of Medicine Intravenous FamotidineGastrointestinal PharmacologyMedicinePhysiologyGastroenterology	1986	37
Pharmacodynamics of famotidine in humans A.N. Chremos The American Journal of Medicine Pharmacological StudyPharmacologyPharmacotherapyMedicineDrug Discovery	1986	35

Page 1